Resource Library Search

IMW 2021: MRD in myeloma

Natalie Callander, MD, of the University of Wisconsin School of Medicine and Public Health, Madison, WI, Luciano Costa, MD, PhD, of the UAB School of Medicine, Birmingham, AL, Fredrik Schjesvold, MD, PhD, of the Oslo Myeloma Center Oslo University, Oslo, Norway, Lanny Kirsch, MD, Senior Vice President in Translational Medicine at Adaptive Biotechnologies, Seattle, WA, and Philippe Moreau, MD, of the Nantes University Hospital, Nantes, France, discuss the latest data on the use of MRD in the management and treatment of multiple myeloma, as presented at the 18th International Myeloma Workshop (IMW 2021).

VJHemeOnc The Video Journal of Hematological Oncology

Lay the Groundwork Learn MRD Testing Methods Multiple Myeloma Prepare the Care Team Timing of MRD Testing Treatment Decision-Making Podcast

A Discussion on MRD: Practical Information for Providers (May 2021)

Dr. Jeffrey Wolf, from the UCSF Helen Diller Family Comprehensive Cancer Center at the University of California San Francisco, explains what MRD is, how providers can explain the role of MRD to patients, including understanding the tests used, how to counsel patients when there is MRD, where testing is done for patients treated in the community, the way MRD test results will be used in the future, and so much more.

Treating Blood Cancers LLS Podcast Series for Professionals

B-cell ALL Lay the Groundwork Learn MRD Testing Methods Multiple Myeloma Prepare the Care Team Timing of MRD Testing Treatment Decision-Making Podcast

Minimal residual disease in multiple myeloma: bringing the bench to the bedside

This Review presents an overview of the various techniques for MRD detection in patients with MM. In addition, this article discusses challenges and opportunities for the routine use of MRD testing, possible future directions for clinical trials and implications for drug approval processes.

Nature reviews. Clinical oncology.

MRD Testing Methods Multiple Myeloma Timing of MRD Testing Treatment Journal Article

Measurable residual disease in multiple myeloma and light chain amyloidosis: more than meets the eye

This review aims to critically analyze the key MRD aspects including the current evidence supporting the use of MRD in clinical practice and the pitfalls of the various methods used to assess MRD. The utility of MRD for light chain (AL) amyloidosis will also be discussed.

Leukemia & Lymphoma

Lay the Groundwork Learn MRD Testing Methods Multiple Myeloma Timing of MRD Testing Journal Article

Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations

This review article presents "the work of an international, multidisciplinary, 174-member panel convened to identify critical questions on key issues pertaining to MRD in chronic lymphocytic leukemia, review evaluable data, develop unified answers in conjunction with local expert input, and provide recommendations for future studies. Recommendations are presented regarding methodology for MRD determination, assay requirements and in which tissue to assess MRD, timing and frequency of assessment, use of MRD in clinical practice versus clinical trials, and the future usefulness of MRD assessment.

Leukemia

Assess Clinical Trials CLL Implement the Initiative Learn MRD Testing Methods Prepare the Care Team Timing of MRD Testing Treatment Decision-Making Journal Article

International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

Minimal residual disease (MRD) assessment is incorporated in an increasing number of multiple myeloma (MM) clinical trials as a correlative analysis, an endpoint or even as a determinant of subsequent therapy. There is substantial heterogeneity across clinical trials in how MRD is assessed and reported, creating challenges for data interpretation and for the design of subsequent studies. We convened an international panel of MM investigators to harmonize how MRD should be assessed and reported in MM clinical trials. The panel provides consensus on which MM trials should include MRD, the recommended time points for MRD assessment, and expected analytical validation for MRD assays.

Leukemia

Clinical Trials Lay the Groundwork Learn Multiple Myeloma Timing of MRD Testing Journal Article

Measurable residual disease in multiple myeloma: ready for clinical practice?

The landscape of multiple myeloma has changed considerably in the past two decades regarding new treatments, insight into disease biology and innovation in the techniques available to assess MRD as the most accurate method to evaluate treatment efficacy. The sensitivity and standardization achieved by these techniques together with unprecedented rates of CR induced by new regimens, raised enormous interest in MRD as a surrogate biomarker of patients� outcome and endpoint in clinical trials. By contrast, there is reluctance and general lack of consensus on how to use MRD outside clinical trials. Here, we discuss critical aspects related with the implementation of MRD in clinical practice.

Journal of Hematology & Oncology

Assess Clinical Trials Implement the Initiative Lay the Groundwork Learn MRD Testing Methods Multiple Myeloma Prepare the Care Team Timing of MRD Testing Treatment Decision-Making Journal Article

Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT

Assessment of MRD is rapidly transforming the therapeutic and prognostic landscape of a wide range of hematological malignancies. Its prognostic value in ALL has been established and MRD measured at the end of induction is increasingly used to guide further therapy. Although MRD detectable immediately before allogeneic HCT is known to be associated with poor outcomes, it is unclear if or to what extent this differs with different types of conditioning.

Journal of Hematology & Oncology

B-cell ALL Lay the Groundwork Learn Timing of MRD Testing Treatment Treatment Decision-Making Journal Article

Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions

This comprehensive review focuses on the recent advances and future directions in novel therapeutic strategies in adult ALL.

Journal of Hematology & Oncology

B-cell ALL Learn Prepare the Care Team Timing of MRD Testing Treatment Treatment Decision-Making Journal Article

Role of imaging in the evaluation of minimal residual disease in multiple myeloma patients

Brief review of imaging-based sensitive response assessment through the use of functional rather than morphological whole-body imaging techniques, such as positron emission tomography with computed tomography and magnetic resonance imaging, as a strategy to overcome limitations of flow-cytometry or molecular-based methods, such as the patchy infiltration of bone marrow plasma cells and the presence of extra-medullary, in evaluating response to therapy and in the assessment of the MRD status in MM patients.

Journal of Clinical Medicine

Lay the Groundwork Learn MRD Testing Methods Multiple Myeloma Prepare the Care Team Timing of MRD Testing Journal Article

Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis

Minimal residual disease (MRD) refers to the presence of disease in cases deemed to be in complete remission by conventional pathologic analysis. Assessing the association of MRD status following induction therapy in patients with ALL with relapse and mortality may improve the efficiency of clinical trials and accelerate drug development.

JAMA Oncology

B-cell ALL Lay the Groundwork Learn Prepare the Care Team Timing of MRD Testing Treatment Decision-Making Journal Article

Minimal residual disease in multiple myeloma: are we there yet?

Brief review article that concludes, "With the approval of several new drugs with different mechanisms of action and the incorporation of MRD as an end-point in clinical trials, the management landscape of MM is changing rapidly. Given the significant impact of MRD negativity on the outcomes, it could be a new regulatory surrogate end-point for survival in clinical trials and a main driver of research and clinical practice in MM in the future.

International Journal of Hematologic Oncology

Clinical Trials Lay the Groundwork Learn Multiple Myeloma Prepare the Care Team Timing of MRD Testing Treatment Treatment Decision-Making Journal Article

Should undetectable minimal residual disease be the goal of chronic lymphocytic leukemia therapy?

This review discusses available methods of minimal residual disease measurement. It summarizes minimal residual disease data from pivotal clinical trials and discusses potential implications for future studies and minimal residual disease-based clinical strategies.

Hematology/Oncology Clinics of North America

Clinical Trials CLL Lay the Groundwork Learn MRD Testing Methods Prepare the Care Team Timing of MRD Testing Journal Article

Minimal residual disease in multiple myeloma: why, when, where

We review the data supporting MRD testing as well as its limitations and how it may fit in with current and future clinical practice.

Hematology

Assess Implement the Initiative Learn Multiple Myeloma Prepare the Care Team Timing of MRD Testing Journal Article

A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia

A systematic literature review and meta-analysis were performed to elucidate the clinical significance of minimal residual disease with respect to relapse-free survival and overall survival in precursor B-cell ALL.

Haematologica

B-cell ALL Lay the Groundwork Learn MRD Testing Methods Prepare the Care Team Timing of MRD Testing Treatment Decision-Making Journal Article

Minimal residual disease in multiple myeloma: current landscape and future applications with immunotherapeutic approaches

This review summarizes current data on MRD in the clinical management of MM, highlights open issues and discusses the challenges and the endless opportunities arising for both patients and clinicians. Furthermore, it focuses on the current status of MRD in clinical trials, its dynamics in addressing debatable aspects in the clinical handling and its potential role as the prevailing factor for future MRD-driven tailored therapies.

Frontiers in Oncology

Clinical Trials Lay the Groundwork Learn Multiple Myeloma Prepare the Care Team Timing of MRD Testing Treatment Journal Article

Minimal residual disease in acute lymphoblastic leukemia: technical and clinical advances

Through a review of the literature and in house data, authors analyze the current status of MRD assessment in ALL to better understand how some of its limitations could be overcome by emerging molecular technologies. Authors highlight the future role of MRD monitoring in the context of personalized protocols, taking into account the genetic complexity in ALL.

Frontiers in Oncology

B-cell ALL Learn MRD Testing Methods Prepare the Care Team Timing of MRD Testing Treatment Decision-Making Journal Article

The evolving use of minimal residual disease (MRD) assessment in chronic lymphocytic leukemia

"This monograph examines clinical trial data regarding the role of MRD in CLL, and provides recommendations on how to incorporate MRD assessment into clinical management."

Clinical Advances in Hematology & Oncology

Assess Clinical Trials CLL Implement the Initiative Lay the Groundwork Learn MRD Testing Methods Prepare the Care Team Timing of MRD Testing Treatment Decision-Making Journal Article

Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma

We explore the important role of the clinical value of MRD use in the real-world practice in MM. We address new topics in the field of MRDs, including the importance of MRD dynamics and prediction of relapse.

Blood Advances

Implement the Initiative Lay the Groundwork Learn Multiple Myeloma Prepare the Care Team Timing of MRD Testing Journal Article

Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials

Although levels of minimal residual disease (MRD) decrease below the detection limit in most adult patients with standard-risk ALL after consolidation treatment, about 30% of these patients will ultimately relapse. To evaluate the power of MRD monitoring as an indicator of impending relapse, we prospectively analyzed postconsolidation samples of 105 patients enrolled in the GMALL trial by real-time quantitative polymerase chain reaction (PCR) of clonal immune gene rearrangements.

Blood

B-cell ALL Clinical Trials Lay the Groundwork Learn MRD Testing Methods Timing of MRD Testing Journal Article

Share

In This Section